Full-Time

Associate Director Manufacturing NPI & Clinical Readiness

Posted on 5/20/2025

Deadline 5/23/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$172.1k - $208.5k/yr

+ Incentive Cash + Stock Opportunities

Expert

Company Historically Provides H1B Sponsorship

Bothell, WA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Bachelor’s or Graduate degree in Engineering, Life Sciences, or related fields.
  • 10+ years of experience in pharmaceutical/biotech manufacturing, with a focus on new product introduction, tech transfer, and process validation.
  • Proven experience leading cross-functional teams and managing complex projects in a regulated cGMP environment.
  • Strong expertise in tech transfer, PPQ execution, and manufacturing readiness.
  • Deep understanding of cGMPs, process validation, and regulatory requirements.
Responsibilities
  • Develop and implement manufacturing readiness plans to ensure smooth integration of new products into commercial manufacturing.
  • Partner with Manufacturing and Quality to identify gaps and execute readiness strategies.
  • Lead risk assessments and mitigation planning to enhance process robustness.
  • Own and drive manufacturing systems that support technology transfer strategies from clinical development through PPQ and commercial launch.
  • Actively support site tech transfer teams during process comparability, process validation, and ensure seamless transition between sites.
  • Collaborate with MSAT and development teams to improve tech transfer methodologies.
  • Lead team of manufacturing through PPQ strategy and execution, ensuring alignment with regulatory expectations.
  • Support the delivery of key PPQ milestones, including ensuring operational readiness, employee training, and data collection—with a safety first, quality always mindset.
  • Support process validation lifecycle, ensuring processes meet regulatory and business requirements.
  • Drive post-PPQ improvements and lifecycle management.
  • Lead manufacturing NPI team and support cross-functional teams to ensure alignment on NPI execution.
  • Serve as a site representative in network-level NPI manufacturing discussions.
  • Communicate progress, risks, and mitigation plans to manufacturing senior leadership and stakeholders.
  • Identify and drive process and operational improvements to enhance NPI efficiency.
  • Implement best practices in tech transfer, PPQ execution, and manufacturing readiness.
  • Leverage digital tools and data analytics for process optimization.
Desired Qualifications
  • Experience with cell therapy or biologics manufacturing preferred.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with BioNTech enhances BMS's oncology portfolio against competitors like Merck.
  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • $40 billion US investment shows BMS's commitment to long-term growth and innovation.

What critics are saying

  • Heavy reliance on real-world data may affect drug approval if data quality falters.
  • $11.1 billion BioNTech partnership could strain finances if results are underwhelming.
  • Recent layoffs may impact operational efficiency and employee morale at BMS.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company integrates real-world data to enhance drug development and patient outcomes.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

Hit Consultant
Jun 10th, 2025
From Raw Records To Real-Time Insights: Climbing Pharma’S Real-World Data Maturity Curve

Viraj Narayanan, CEO at Cornerstone AI Daniel Lane, Head of RWD Strategy & Operations at Bristol Myers SquibbReal-world data (RWD) has become the pharmaceutical industry’s most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and repeatable approach to data quality, as well as a strategic roadmap that moves an organization from minimal use of RWD to a position of true leadership. This journey isn’t simple, but for those committed to navigating it, the competitive advantages are substantial. And, importantly, RWD holds the potential to help bring lifesaving and life-changing medications to market faster and safer than ever before.From Data Collection to MaturityPharma’s growing reliance on RWD has encouraged an influx of partnerships with data aggregators, medical institutions, and digital health platforms. Yet, not all companies are at the same level of maturity in using that data effectively

Devdiscourse
Jun 2nd, 2025
Reuters Health News Summary

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

The Motley Fool
Jun 2nd, 2025
Why BioNTech Stock Soared Today

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327.

INACTIVE